To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
273actual
Sites
141
Countries
Belgium, Canada, Czechia +12
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-03-07 | actual | When the study began enrolling |
| Primary completion | 2020-11-13 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-10-09 | estimated | The whole study's end, after follow-up |
| First posted | 2017-11-06 | actual | When this record first appeared on the registry |
| Results posted | 2022-03-22 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-07-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Triple Negative Breast Cancer
Interventions
- Drug: Olaparib Continuous (28-Day cycle) 300 mg BD.
- Drug: Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).
- Drug: Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).
Primary outcomes
what the primary-completion date above is the date OFProgression-free Survival Per Stratum (BICR)
measured Until date of first documented progression or censoring date or date of death from any cause, whichever came first (assessed up to 32 months)
Progression-free Survival Per Stratum (Sensitivity Analysis)
measured Until date of first documented progression or censoring date or date of death from any cause, whichever came first (assessed up to 32 months)
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2020-05-06 · 1.5 MB · Prot_000.pdf
Statistical Analysis Planposted 2019-06-14 · 2.1 MB · SAP_001.pdf
Publications
- PMID 34904813 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed